Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150
Vascular Pharmacology · 2025-06 · 159 · 107487
DOI: 10.1016/j.vph.2025.107487 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Pharmacology, 2025-06. Verfasst von Magalì Giordano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, TO 10043, Italy. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Myocytes, Cardiac, Inflammasomes, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Università degli Studi di Torino.
Abstract (Originalsprache)
BACKGROUND: Cardiovascular diseases remain the leading cause of disability and death in the Western world. Effective cardioprotection involves limiting ischemia/reperfusion injury (IRI), including cell death (pyroptosis) driven by the NLRP3 inflammasome. While various cardiac resident cellular populations contribute to cardioprotection, it remains unclear whether targeting resident macrophages is inherently cardioprotective. Given that INF150, an NLRP3 inhibitor, exhibits varying abilities to penetrate cardiomyocytes and macrophages, we sought to address this question. METHODS: We studied the cardioprotective potential of INF150, the potent metabolite of the NLRP3 inhibitor INF195, in isolated hearts or cells. In isolated hearts, we measured infarct size, caspase-1 cleavage, and interleukins (IL) release, while in macrophages, naïve H9c2 and differentiated H9c2 cells, we analyzed cell viability, and pyroptosis markers, including IL-1β release and Gasdermin D cleavage, following hypoxia/reoxygenation (H/R). RESULTS AND CONCLUSION: While INF150 effectively shielded macrophages from LPS/ATP challenges, it failed to penetrate H9c2 and differentiated H9c2, even at high concentrations (no changes in pyroptosis markers induced by H/R). In the isolated mice heart model, INF150 did not demonstrate cardioprotective effects: infarct size, IL-1β, cleaved caspase-1 levels did not change significantly across tested concentrations of INF150. These findings suggest that while INF150 shows promise in macrophage/phagocytic models, its inability to penetrate cardiomyocytes limits its effectiveness in the whole cardiac tissue. Our results underscore the importance of cardiomyocyte uptake for effective cardioprotection, highlighting the need for NLRP3 inhibitors capable of targeting these cells directly. Future research should focus on enhancing the delivery and cardiomyocyte uptake of NLRP3 inhibitors to achieve cardioprotection. Unlike its precursor, INF195, which penetrates H9c2 cells, INF150 does not appear to offer cardioprotection in the whole organ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, TO 10043, Italy.
- Department of Drug Science and Technology, University of Turin, Via P. Giuria 9, 10125 Torino, Italy.
- Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, TO 10043, Italy; National Institute for Cardiovascular Research (INRC), 40126 Bologna, Italy.
- Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, Orbassano, TO 10043, Italy; National Institute for Cardiovascular Research (INRC), 40126 Bologna, Italy. Electronic address: pasqu…
Förderung
- Ministero dell'Università e della Ricerca
- Università degli Studi di Torino
Zitieren
APA
Giordano, M., Femminò, S., Blua, F., Boccato, F., Rubeo, C., Mantuano, B., Cioffi, F., Comità, S., Brovero, A., Ciullo, R., Bertinaria, M., Penna, C., & Pagliaro, P. (2025). Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150. Vascular Pharmacology, 159, 107487. https://doi.org/10.1016/j.vph.2025.107487
Vancouver
Giordano M, Femminò S, Blua F, Boccato F, Rubeo C, Mantuano B, et al. Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150. Vascular Pharmacology. 2025;159:107487. doi:10.1016/j.vph.2025.107487
BibTeX
@article{Giordano2025,
author = {Giordano, Magalì and Femminò, Saveria and Blua, Federica and Boccato, Francesca and Rubeo, Chiara and Mantuano, Beatrice and Cioffi, Francesca and Comità, Stefano and Brovero, Arianna and Ciullo, Rosa and Bertinaria, Massimo and Penna, Claudia and Pagliaro, Pasquale},
title = {Macrophage and cardiomyocyte roles in cardioprotection: Exploiting the NLRP3 Inflammasome inhibitor INF150},
journal = {Vascular Pharmacology},
year = {2025},
volume = {159},
pages = {107487},
doi = {10.1016/j.vph.2025.107487}
}
EUVIMED